Abstract
Background
Objective
Methods
Results
Conclusions
Key words
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical TherapeuticsReferences
- Surveillance for acute viral hepatitis—United States, 2007.MMWR Surveill Summ. 2009; 58: 1-27
- Sexually transmitted diseases treatment guidelines, 2010.MMWR Recomm Rep. 2010; 59 ([published correction appears in MMWR Recomm Rep. 2011;60:18]): 1-110
- Naives, nonresponders, relapsers: who is there left to treat?.Clin Liver Dis. 2011; 15: 483-495
- Boceprevir: a protease inhibitor for the treatment of chronic hepatitis C.Ann Pharmacother. 2011; 45: 1085-1093
- Emerging therapies in hepatitis C: dawn of the era of the direct-acting antivirals.Gastroenterol Clin North Am. 2011; 40: 481-494
- Directly acting antivirals for hepatitis C and antiretrovirals: potential for drug-drug interactions.Curr Opin HIV AIDS. 2011; 6: 514-526
- A new standard of care for the treatment of chronic HCV infection.Nat Rev Gastroenterol Hepatol. 2011; 8: 257-264
- Challenges in modern drug discovery: a case study of boceprevir, an HCV protease inhibitor for the treatment of hepatitis C virus infection.Acc Chem Res. 2008; 41: 50-59
- Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034).Antimicrob Agents Chemother. 2009; 53: 401-411
- Boceprevir: a user's guide.Clin Liver Dis. 2011; 15: 537-553
- New insights into HCV replication: potential antiviral targets.Top Antivir Med. 2011; 19: 117-120
- Introduction: a smouldering public-health crisis.Nature. 2011; 474: S2-S4
- Boceprevir for previously treated chronic HCV genotype 1 infection.N Engl J Med. 2011; 364: 1207-1217
- Discovery of novel P3 sulfonamide-capped inhibitors of HCV NS3 protease.Bioorg Med Chem. 2009; 17: 4486-4495
- Hepatitis in 2010: the dawn of a new era in HCV therapy.Nat Rev Gastroenterol Hepatol. 2011; 8: 69-71
- Big changes are coming in hepatitis C.Curr Gastroenterol Rep. 2011; 13: 72-77
- Hepatitis C protease and polymerase inhibitors in development.AIDS Patient Care STDS. 2008; 22: 449-457
- Victrelis.([package insert]) Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc, Whitehouse Station, NJ2011 (Accessed July 30, 2012)
- Incivek.([package insert]) Vertex Pharmaceuticals Incorporated, Cambridge, MA2012 (Accessed July 30, 2012)
- Future of hepatitis C therapy: development of direct-acting antivirals.Curr Opin HIV AIDS. 2011; 6: 508-513
- STAT-C: a full revolution or just a step forward?.Lancet. 2010; 376: 662-663
- Excitement grows for potential revolution in hepatitis C virus treatment.Nat Rev Drug Discov. 2010; 9: 501-503
- Perspective: miles to go before we sleep.Nature. 2011; 474: S8
- The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending.Gastroenterology. 2011; 140: 746-754
- Boceprevir for untreated chronic HCV genotype 1 infection.N Engl J Med. 2011; 364: 1195-1206
- Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naïve patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomized, multicentre Phase 2 trial.Lancet. 2010; 376: 705-716
- The journey to the discovery of boceprevir: an NS3-NS4 HCV protease inhibitor for the treatment of chronic hepatitis C.Prog Med Chem. 2010; 49: 1-36
- Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino]carbonyl]amino]-3,3-dimethyl-1-oxobutyl]-6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection.J Med Chem. 2006; 49: 6074-6086
Zhang J, Gupta S, Rouzier R, et al. Single dose pharmacokinetics of a novel hepatitis C protease inhibitor, SCH 503034, in an oral capsule formulation. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 862.
Zeuzem S, Sarrazin C, Rouzier R, et al. Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in hepatitis C genotype-1 (HCV-1) patients refractory to pegylated interferon (PEG-IFN-α). Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 94.
Zeuzem S, Sarrazin C, Wagner F, et al. Combination therapy with the HCV protease inhibitor, SCH 503034, plus peg-intron in hepatitis C genotype-1 peg-intron non-responders: Phase IB results. Abstract presented at: 56th Annual Meeting of the American Association for the Study of Liver Diseases; November 11–15, 2005; San Francisco, Calif. Abstract 201.
Preston R, Alonso A, Feely W, et al. SCH 503034, an oral HCV protease inhibitor, is well-tolerated in patients with varying degrees of hepatic impairment. Abstract presented at: 42nd Annual Meeting of the European Association for the Study of the Liver; April 11–15, 2007; Barcelona, Spain. Abstract 545.
- Single-dose pharmacokinetics of boceprevir in subjects with impaired hepatic or renal function.Clin Pharmacokinet. 2012; 51: 619-628
- Characterization of human liver enzymes involved in the biotransformation of boceprevir, a hepatitis C virus protease inhibitor.Drug Metab Dispos. 2011; 39: 510-521
- Review article: specifically targeted anti-viral therapy for hepatitis C—a new era in therapy.Aliment Pharmacol Ther. 2010; 32: 14-28
- New HCV therapies on the horizon.Clin Microbiol Infect. 2011; 17: 122-134
- The role of triple therapy with protease inhibitors in hepatitis C virus genotype 1 naïve patients.Liver Int. 2011; 31: 53-57
- New direct-acting antivirals' combination for the treatment of chronic hepatitis C.Liver Int. 2011; 31: 68-77
- Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients.Hepatology. 2009; 50: 1709-1718
- Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus.Hepatology. 2011; 53: 1742-1751
- A new era of hepatitis C therapy.N Engl J Med. 2011; 364: 1272-1274
- Directly acting antivirals against hepatitis C virus.J Antimicrob Chemother. 2011; 66: 1673-1686
- Drugs in development for viral hepatitis: care and caution.Drugs. 2011; 71: 263-271
- Boceprevir.Hepatology. 2011; 54: 2254-2257
- A sprint to increase response to HCV treatment: expectancies but caution.J Hepatol. 2011; 55: 1154-1158
- Boceprevir (Victrelis) for HCV: V is for victory and very complex.Hepatology. 2011; 54: 1882-1886
- SCH 503034, a novel hepatitis C virus protease inhibitor, plus pegylated interferon alpha-2b for genotype 1 nonresponders.Gastroenterology. 2007; 132: 1270-1278
- Update on viral hepatitis: 2007.Curr Opin Gastroenterol. 2008; 24: 306-311
- Treatment of hepatitis C: don't put all your eggs in one basket!.Gastroenterology. 2007; 132: 1611-1615
- Drugs in development for chronic hepatitis C: a promising future.Expert Opin Biol Ther. 2011; 11: 1611-1622
- Therapeutics: new drugs hit the target.Nature. 2011; 474: S5-S7
- NDA 202258.(Accessed July 31, 2012)
- Formulary management of the protease inhibitors boceprevir and telaprevir for chronic hepatitis C virus.J Manag Care Pharm. 2011; 17: 685-694
- Boceprevir for chronic HCV genotype 1 infection.N Engl J Med. 2011; 365: 176
- Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.Hepatology. 2008; 48: 1769-1778
- Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects.J Infect Dis. 2008; 198: 800-807
- Analysis of long-term persistence of resistance mutations within the hepatitis C virus NS3 protease after treatment with telaprevir or boceprevir.J Clin Virol. 2011; 52: 321-327
- Characterization of resistance mutations against HCV ketoamide protease inhibitors.Antiviral Res. 2008; 77: 177-185
- Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.Virology. 2008; 370: 237-245
- Analysis of HCV resistance mutations during combination therapy with protease inhibitor boceprevir and PEG-IFN alpha-2b using TaqMan mismatch amplification mutation assay.J Virol Methods. 2008; 153: 156-162
- Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding.Proc Natl Acad Sci U S A. 2010; 107: 20986-200991
- Mixing and matching drugs: what makes sense?.Clin Liver Dis. 2011; 15: 657-664
- Mechanisms of non-response to antiviral treatment in chronic hepatitis C.Clin Res Hepatol Gastroenterol. 2011; 35: S31-S41
- A novel HCV NS3 protease mutation selected by combination treatment of the protease inhibitor boceprevir and NS5B polymerase inhibitors.Antiviral Res. 2009; 84: 178-184
- Preclinical characterization of the antiviral activity of SCH 900518 (narlaprevir), a novel mechanism-based inhibitor of hepatitis C virus NS3 protease.Antimicrob Agents Chemother. 2010; 54: 2365-2370
- Progress towards improving antiviral therapy for hepatitis C with hepatitis C virus polymerase inhibitors.Expert Opin Investig Drugs. 2009; 18: 709-725
- Hepatitis C drug development at a crossroads.Hepatology. 2009; 50: 997-999
- Specific detection of naturally occurring hepatitis C virus mutants with resistance to telaprevir and boceprevir (protease inhibitors) among treatment-naïve infected individuals.J Clin Microbiol. 2012; 50: 281-287
- Susceptibility of treatment-naïve hepatitis C virus (HCV) clinical isolates to HCV protease inhibitors.Antimicrob Agents Chemother. 2010; 54: 5288-5297
- In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435.Antimicrob Agents Chemother. 2010; 54: 1878-1887
- The HIV/HCV-coinfected patient and new treatment options.Clin Liver Dis. 2011; 15: 585-596
- Telaprevir, boceprevir, cytochrome P450 and immunosuppressive agents—a potentially lethal cocktail.Hepatology. 2011; 54: 3-5
- New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals.J Antimicrob Chemother. 2012; 65: 1079-1085
- Telaprevir for the treatment of chronic hepatitis C infection.Expert Rev Anti Infect Ther. 2011; 9: 1105-1114
- The critical role of medication adherence in the success of boceprevir and telaprevir in clinical practice.J Hepatol. 2012; 56: 503-504
- Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment.Hepatology. 2012; 55: 1048-1057
- Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C.Hepatology. 2012 Mar 27; ([Epub ahead of print].)
- Effect of discounting on estimation of benefits determined by hepatitis C treatment.World J Gastroenterol. 2012; 18: 3032-3034
- 2011 Drug Topics Red Book.Thomson Medical Economics, Montvale, NJ2011